Health.Global

Q1 FY27Healthcare Services

Health.Global Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹720

Market cap₹10.8K Cr

P/E225.0

Updated25 Aug 2026

Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueRank 3

MarginRank 1

CapexYes

FundraiseYes

Not discussed on this call: order book.

The short version

Confident in delivering mid-teens revenue growth from existing centers and new greenfield and brownfield expansions. Management targets EBITDA margins of 21%-22% in the next 2 years, progressing to 24%-25% in 4-5 years.

From Health.Global's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3

Confident in delivering mid-teens revenue growth from existing centers and new greenfield and brownfield expansions.
Expect 11% year-on-year volume growth, supported by strong patient demand.
Planned addition of 65 beds in FY27, 520 beds in FY28 and FY29, and 230 beds in FY30 to drive capacity expansion.
Growth to be broad-based with increased utilization and ramp-up of new facilities like North Bangalore hospital.
Anticipate steady improvement in payor mix, case mix complexity, and clinical capabilities supporting revenue quality.
ARPP growth expected in line with inflation (~2%).
Strategic focus on more complex clinical work and enhanced patient experience likely to support sustainable top-line momentum.
New technologies and clinical talent investments to aid higher value services and referrals.
Long-term outlook remains robust with financial flexibility to fund expansion while maintaining disciplined capital allocation.

Profitability & Margins

Management targets EBITDA margins of 21%-22% in the next 2 years, progressing to 24%-25% in 4-5 years.
Revenue growth outlook remains at mid-teens CAGR, driven by both organic growth in existing centers and capacity expansion.
Payor mix improvement is the key lever for margin expansion, alongside enhanced clinical offerings and operating leverage from maturing centers.
North Bangalore hospital is expected to ramp up steadily, reducing losses and contributing to profitability.
Marketing spend will be maintained around 2.5%-2.9% of sales to support volume growth.
Expansion plans include adding 65 beds in FY27 and substantial capacity additions in FY28-FY30, supporting future revenue growth.
Operational excellence initiatives in cost optimization and productivity improvements will further enhance margins.
Overall, the company is confident of delivering consistent, sustainable, and profitable growth with improved quality of earnings.

See what Health.Global said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Q1 Capex incurred: Approximately INR 75 crore (INR 35 crore growth capex + INR 40 crore maintenance capex).
Full-year maintenance capex expected: Approximately INR 100 crore.
Capacity expansion plans:
- Additional 65 beds in FY27.
- 520 beds across FY28 and FY29, mainly through brownfield projects (~60%) for faster execution and low capex, and 3 greenfield projects in pipeline.
- 230 beds planned in FY30.
Greenfield projects:
- Two greenfield projects adding 180 beds in FY28 and FY29: One in South cluster (Whitefield), likely operational by end of FY28; another in Maharashtra, West cluster, expected later.
Strategic investments:
- Increased shareholding in Vizag hospital from 51% to 85% with INR 150 crore deployment.
- Investment in advanced technology (e.g., MR-LINAC, surgical robots) and clinical capabilities ongoing.
Proceeds from rights issue used partially for debt repayment (INR 170 crore) and corporate purposes.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

- The company has recently completed a rights issue, using proceeds for debt repayment (INR170 crore), increasing shareholding in Vizag hospital, and general corporate purposes. - Interest costs have come down due to this debt repayment. - The company plans to continue funding growth through a mix of debt and internal accruals. - Interest costs are expected to moderate compared to last year but will fluctuate year to year. - There is no explicit mention of imminent new fundraising through debt or equity in the near term. - The company remains open to value-accretive M&A opportunities aligned with their strategy. In summary, while no immediate new fundraising initiatives were stated, the company will balance growth funding with both debt and internal cash, maintaining financial prudence.

See what Health.Global said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript and presentation do not provide specific details regarding the current or expected order book or pending orders for the company. Information available focuses on operational performance, revenue growth, margin outlook, bed capacity expansion, and strategic investments, but no mention of order book figures or pending order statuses is made. Key related points: - Capacity expansions planned: 65 beds in FY27, 520 beds in FY28 and FY29, and 230 beds in FY30. - Three greenfield projects are in the pipeline, with further details to be shared once finalized. - Brownfield expansions constitute nearly 60% of planned capacity growth. - Focus on improving payor mix, clinical complexity, and margin expansion over next 4-5 years. - No direct references to order book or pending orders in the available transcript excerpts.

Health.Global — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹652 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Healthcare Global Enterprises Ltd's management said in earlier quarters

Others in Healthcare Services this season

Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Health.Global Q1 FY27 results?

What is Health.Global share price analysis?

Health.Global currently shows a below-average growth signal. The stock trades at a P/E of 225.0 with a market cap of ₹10,839 Cr. Investors should review the full earnings analysis for detailed insights.

Is Health.Global planning capital expenditure?

Q1 Capex incurred: Approximately INR 75 crore (INR 35 crore growth capex + INR 40 crore maintenance capex).

Keep Health.Global on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.